FindTrial
Sign In

CYD Dengue Vaccine

BIOLOGICAL9 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

DengueDengue DiseasesDengue FeverDengue Hemorrhagic FeverDengue VirusHuman Immunodeficiency VirusHuman Papillomavirus Disease

Phase 2

Efficacy and Safety of Dengue Vaccine in Healthy Children
CompletedNCT00842530
Sanofi Pasteur, a Sanofi CompanyDengue Diseases, Dengue Fever, Dengue Hemorrhagic Fever +1
Start: 2009-02-28End: 2014-02-28Updated: 2022-04-05
Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
CompletedNCT00880893
Sanofi Pasteur, a Sanofi CompanyDengue Diseases, Dengue Fever, Dengue Hemorrhagic Fever +1
Start: 2009-04-07End: 2014-10-14Updated: 2022-03-21
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
CompletedNCT00993447
Sanofi Pasteur, a Sanofi CompanyDengue, Dengue Fever, Dengue Hemorrhagic Fever +1
Start: 2009-10-31End: 2012-03-31Updated: 2022-03-24
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
CompletedNCT01943825
Sanofi Pasteur, a Sanofi CompanyDengue, Dengue Fever, Dengue Hemorrhagic Fever
Start: 2013-11-05End: 2015-11-25Updated: 2022-03-24
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
CompletedNCT02628444
Sanofi Pasteur, a Sanofi CompanyDengue Fever, Dengue Hemorrhagic Fever
Start: 2016-05-02End: 2020-04-29Updated: 2022-03-24
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
CompletedNCT02741128
Sanofi Pasteur, a Sanofi CompanyDengue Fever, Dengue Hemorrhagic Fever, Human Immunodeficiency Virus
Start: 2019-11-06End: 2023-01-19Updated: 2024-07-19

Phase 3

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®
CompletedNCT02979535
Sanofi Pasteur, a Sanofi CompanyDengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
Start: 2016-11-16End: 2019-03-25Updated: 2022-03-25
Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects
TerminatedNCT02992418
Sanofi Pasteur, a Sanofi CompanyDengue Fever, Dengue Hemorrhagic Fever
Start: 2016-12-19End: 2019-12-10Updated: 2022-03-25
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®
CompletedNCT02993757
Sanofi Pasteur, a Sanofi CompanyDengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
Start: 2016-12-01End: 2019-05-27Updated: 2022-03-25

Related Papers

Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial.
2025-11-10
Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18–50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial
2025-01-01
Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18–50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial
OPAL (Open@LaTrobe) (La Trobe University)2025-01-01
Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
2022-03-296 citations
Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data
eLife2021-07-0217 citations
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9–13 Years of Age in Malaysia
The Pediatric Infectious Disease Journal2021-06-246 citations
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine
The Pediatric Infectious Disease Journal2021-06-103 citations
Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico
Vaccine2021-05-137 citations
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
Clinical Infectious Diseases2021-04-0221 citations
Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
2020-11-1617 citations
Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4–5 Years Earlier in Latin America
The Pediatric Infectious Disease Journal2020-09-126 citations
Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series
Human Vaccines & Immunotherapeutics2019-08-2911 citations
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
New England Journal of Medicine2018-06-13755 citations
Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction.
2016-04-1818 citations
Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
2015-10-20121 citations
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
New England Journal of Medicine2015-07-271054 citations
Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore
Human Vaccines & Immunotherapeutics2013-08-1550 citations
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
2012-09-11628 citations
Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.
2012-08-1665 citations